LTR Pharma Limited (ASX:LTP)

Australia flag Australia · Delayed Price · Currency is AUD
0.3950
+0.0100 (2.60%)
At close: May 2, 2025, 4:00 PM AEST
58.00%
Market Cap 70.58M
Revenue (ttm) 499.71K
Net Income (ttm) -6.82M
Shares Out 180.98M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 22,227
Average Volume 87,933
Open 0.3900
Previous Close 0.3850
Day's Range 0.3900 - 0.4000
52-Week Range 0.2450 - 2.1600
Beta n/a
RSI 46.00
Earnings Date May 27, 2025

About LTR Pharma

LTR Pharma Limited, a biopharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol LTP
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.